RNS Number:7321K
Arana Therapeutics Limited
28 December 2007


For Immediate Release                                           28 February 2007


                           Arana Therapeutics Limited


                    Arana announces resignation of director


Arana Therapeutics Limited, (AIM: AAHx ASX: AAH) (the "Company"), the Australian
biopharmaceutical company that uses superior technology to develop next
generation drugs that will improve the lives of patients with inflammatory
diseases and cancer has today announced that Bill Bartlett, to comply with US
governance practice, has had to reduce the number of public company boards on
which he serves as a director. He has therefore resigned, with immediate effect,
from the board of Arana Therapeutics Limited. Mr Bartlett is a director of NYSE
listed company Reinsurance Group of America, as well as ASX listed companies
Suncorp-Metway Limited, Abacus Property Group and GWA International.


Arana Therapeutics Chairman, Robin Beaumont said "Bill has made a significant
contribution to the Arana board over many years bringing not only his extensive
accounting experience but also a very sharp commercial mind."


"We thank Bill for his contribution to Arana. The company is now well positioned
with strong financial resources, our lead product, ART621 is entering Phase II
trials in 2008 and we have a healthy product pipeline." he added.


About Arana Therapeutics:


Arana Therapeutics (ASX: AAH; AIM: AAHx) is an international biopharmaceutical
company formed through the merger of Peptech and EvoGenix in August 2007. The
company uses superior technology to develop next generation drugs that will
improve the lives of patients with inflammatory diseases and cancer.


Arana Therapeutics' innovative technologies provide the basis for clinical
development in the antibody space, a market which draws on high demand. With a
market capitalisation of around A$250 million and solid cash resources, Arana
Therapeutics has the financial stability and management expertise to accelerate
its clinical programs, and is on track to have at least 3 clinical stage assets
within three years.


Arana is listed on the Australian Securities Exchange (ASX) and the London Stock
Exchange (AIM).


The company's pipeline consists of four lead drug programs: ART621 to treat
severe rheumatoid arthritis and other inflammatory diseases; ART010 to treat
osteoporosis and bone cancer; ART104 to treat solid tumours in colorectal
cancer; and ART150 for lung cancer and melanoma. Additionally, the company has
earlier stage products in development for the treatment of a range of conditions
including age related macular degeneration, psoriasis, colorectal cancer, and
leukaemia.


Arana has recurring revenues from commercial and development partnerships with
six international companies including GSK, CSL, Centocor (J&J) and Abbott
Laboratories.


For further information: www.arana.com


Contact information:

Arana Therapeutics Limited
Dr John Chiplin, Chief Executive Officer             +61 (0)2 8061 9900
Niall Henderson, Chief Financial Officer             +61 (0)2 8061 9900

Buchanan Communication
Lisa Baderoon/Rebecca Skye Dietrich                 +44 (0)20 7466 5000

Nomura Code Securities
Charles Walker                                      +44 (0)20 7776 1206




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
BOAUWVKRBBRUURA
Arana Therap. (LSE:AAHX)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Arana Therap. Charts.
Arana Therap. (LSE:AAHX)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Arana Therap. Charts.